Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose ...
Understanding how these functions impact a given compound is essential for effective preclinical drug development. Hepatocytes comprise approximately 80 % of the liver’s volume but only represent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results